All In Biotech

Free tool

FAERS Monitor: Dymista

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202236 or its brand name (Dymista, Azelastine Hydrochloride, Fluticasone Propionate). Reports on generic versions are filed under their own applications.

Reports

4,131

Serious

2,443

59% of reports

Hospitalization

913

Death reported

65

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea328
  • drug ineffective311
  • fatigue287
  • headache278
  • asthma267
  • cough256
  • nausea241
  • sinusitis204
  • pneumonia202
  • dizziness180
  • off label use176
  • diarrhoea158
  • malaise148
  • condition aggravated139
  • pain138

Reports by year received

View as table
YearReports
20101
20125
201319
201472
2015556
2016444
2017334
2018366
2019395
2020390
2021272
2022257
2023254
2024321
2025266
2026179

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,028 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
asthmaSignal26712.110.72,704
sinusitisSignal20410.28.91,679
coughSignal2564.74.1739
pneumoniaSignal2023.22.8304
dyspnoeaSignal3283.02.7433
condition aggravatedSignal1392.32.0105
headacheSignal2782.32.0199
fatigue2871.91.7121
dizziness1801.81.670
malaise1481.71.545
nausea2411.61.448
diarrhoea1581.21.18
drug ineffective3111.21.111
pain1381.11.02
off label use1761.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.